Cost of Revenue Comparison: Zoetis Inc. vs Exelixis, Inc.

Cost of Revenue: A Tale of Two Biopharma Giants

In the competitive world of biopharmaceuticals, understanding cost structures is crucial. Zoetis Inc. and Exelixis, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Zoetis consistently reported a cost of revenue that dwarfed Exelixis, with figures peaking at $2.71 billion in 2023. This represents a 58% increase from 2014. In contrast, Exelixis saw a dramatic rise, with costs surging over 3,400% from $2 million in 2014 to $72 million in 2023. This stark difference highlights Zoetis's established market presence and Exelixis's rapid growth trajectory. The data underscores the diverse strategies these companies employ to manage production costs, reflecting broader industry trends. As Zoetis continues to leverage its scale, Exelixis's aggressive expansion could reshape the competitive landscape. This analysis provides a window into the evolving dynamics of the biopharma sector.